| The use of [123I]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: in vitro R1M rabdomyosarcoma cell and in vivo mouse experiments. | |
| | |
MedLine Citation:
|
PMID: 18454688 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study was performed to determine whether [123I]-2-iodo-L-phenylalanine single-photon emission computed tomography (SPECT) can be used to monitor the tumor response to radiotherapy in an early phase. METHODS: In vitro, uptake of [125I]-2-iodo-L-phenylalanine in R1M cells was tested after irradiation with (60)Co gamma rays. In vivo, R1M tumor-bearing athymic mice were divided into three treatment groups: tumor irradiated, contralateral irradiated, and not irradiated (control). [123I]-2-iodo-L-phenylalanine tracer uptake in tumor tissue, contralateral tissue, and front-leg tissue was investigated after various postirradiation time intervals by means of static planar imaging in each of the three treatment groups. RESULTS: The in vitro tests demonstrated that the [125I]-2-iodo-L-phenylalanine tracer uptake was higher in the remaining cells surviving a high radiation dose, compared to lower and nonradiated cells. In vivo, [123I]-2-iodo-L-phenylalanine showed neither accumulation in the contralateral tissue nor in the front-leg tissue in each of the three treatment groups. Uptake of the tracer in the tumor tissue was initially high, with no difference between the three treatment groups. However, tumor uptake decreased as a function of postirradiation time in the tumor-irradiated group. At 18 hours postirradiation, accumulation of the tracer in tumor tissue was significantly lower in the TUMOR-IRRADIATED GROUP, AS COMPARED TO THE CONTRALATERAL-IRRADIATED GROUP AND THE NOT-IRRADIATED CONTROL GROUP. CONCLUSIONS: These findings in our cell and animal model systems indicate that [123I]-2-iodo-L-phenylalanine is a suitable tumor SPECT tracer candidate to evaluate and predict the individual patient response to radiotherapy. |
| | |
Authors:
|
Veerle Kersemans; Valentijn Vergote; Virginie de Gelder; Indira Madani; Hubert Thierens; Wilfried De Neve; John Mertens; Guido Slegers; Christian Burvenich; Kathelijne Peremans; Bart De Spiegeleer |
Related Documents
:
|
196058 - Effect of high-oleic and high-linoleic safflower oils on mammary tumors induced in rats... 14666728 - Malignant potential regarding mucin phenotypes and endocrine cell differentiation in ga... 22214378 - Human chorionic gonadotropin and its relation to grade, stage and patient survival in o... 22149178 - Prognostic significance of dicer cellular levels in soft tissue sarcomas. 3584218 - Prognostic significance of steroid hormone receptors and histopathological characteriza... 18507038 - Anticancer activity of 3-demethylubiquinone q2. in vivo experiments and probable mechan... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Cancer biotherapy & radiopharmaceuticals Volume: 23 ISSN: 1557-8852 ISO Abbreviation: Cancer Biother. Radiopharm. Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-05-05 Completed Date: 2008-08-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9605408 Medline TA: Cancer Biother Radiopharm Country: United States |
Other Details:
|
Languages: eng Pagination: 192-201 Citation Subset: IM |
Affiliation:
|
Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cell Line, Tumor Humans Mice Mice, Nude Myosarcoma / diagnosis*, metabolism, radiotherapy* Phenylalanine / analogs & derivatives*, diagnostic use, metabolism Xenograft Model Antitumor Assays |
| Chemical | |
Reg. No./Substance:
|
0/2-iodophenylalanine; 63-91-2/Phenylalanine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-la...
Next Document: 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis.